News & Updates

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.

Children with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of type 2 diabetes, a study reports. Other risk factors for T2D include severity of liver histology, body mass index, and female sex.

Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.

Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.

Insulin resistance in young people with obesity is positively associated with an atherogenic lipoprotein/lipid profile and carotid intima-media thickness (cIMT), regardless of their glucose tolerance status, suggests a study.